Acta Pharmaceutica Sinica B · 2024 · 15 citations · 36 references
MedicineImmunologyOncologyMetastasisTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyChemokine NetworksChemokine SignalingMyeloid-derived Suppressor CellsTumor Immune MicroenvironmentTumor Microenvironment ModulationCytokine-mediated Tumor Microenvironment ModulationCytotoxic T Lymphocyte InfiltrationGranulocytic Myeloid-derived Suppressor CellsKnockout Mouse ModelsMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell-mediated SuppressionPrecision ImmunotherapyTumor Microenvironment Regulation
SMAD4 deficiency in colorectal cancer (CRC) is highly correlated with liver metastasis and high mortality, yet there are few effective precision therapies available. Here, we show that CCR1+-granulocytic myeloid-derived suppressor cells (G-MDSCs) are highly infiltrated in SMAD4-deficient CRC via CCL15/CCR1 and CCL9/CCR1 axis in clinical specimens and mouse models, respectively. The excessive TGF-β, secreted by tumor-infiltrated CCR1+-G-MDSCs, suppresses the immune response of cytotoxic T lymphocytes (CTLs), thus facilitating metastasis. Hereby, we develop engineered nanovesicles displaying CCR1 and TGFBR2 molecules (C/T-NVs) to chemotactically target the tumor driven by CCL9/CCR1 axis and trap TGF-β through TGF-β-TGFBR2 specific binding. Chemotactic C/T-NVs counteract CCR1+-G-MDSC infiltration through competitive responding CCL9/CCR1 axis. C/T-NVs-induced intratumoral TGF-β exhaustion alleviates the TGF-β-suppressed immune response of CTLs. Collectively, C/T-NVs attenuate liver metastasis of SMAD4-deficient CRC. In further exploration, high expression of programmed cell death ligand-1 (PD-L1) is observed in clinical specimens of SMAD4-deficient CRC. Combining C/T-NVs with anti-PD-L1 antibody (aPD-L1) induces tertiary lymphoid structure formation with sustained activation of CTLs, CXCL13+-CD4+ T, CXCR5+-CD20+ B cells, and enhanced secretion of cytotoxic cytokine interleukin-21 and IFN-γ around tumors, thus eradicating metastatic foci. Our strategy elicits pleiotropic antimetastatic immunity, paving the way for nanovesicle-mediated precision immunotherapy in SMAD4-deficient CRC.
36
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations
Life Sciences, Immunology, Oncology +16
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Zvi G. Fridlender, Jing Sun, Samuel Kim et al. · Cancer Cell · 2009 · 3.3K citations · Full text
Medicine, Immunology, Oncology +12
Masaki Terabe, So Matsui, Jong-Myun Park et al. · The Journal of Experimental Medicine · 2003 · 536 citations · Full text
Life Sciences, Immunology, Oncology +17
Cryosectioning and immunolabeling
Jan W. Slot, Hans J. Geuze · Nature Protocols · 2007 · 455 citations